How much has AKASA raised?

Company and investor coverage place AKASA above $200M raised, with Business Insider citing $250M total. The public record clearly includes a $60M Series B and $125M Series C; early seed and Series A details are less fully itemized in public snippets but a16z is identified as an early lead investor.

a16z backed AKASA early and appears on the official investment list. Coatue led the Series C, while BOND, Costanoa Ventures, and other investors are cited in company and secondary-market materials. The investor mix signals a high-conviction healthcare-enterprise software company rather than a narrow RPA tool.

AKASA has not disclosed a latest valuation. Valuation pressure and upside likely depend on health-system contract expansion, demonstrable recovered revenue, AI coding accuracy, compliance defensibility, and implementation scalability.

AKASA is private and has not announced profitability or IPO plans. A near-term IPO is not publicly signaled; the more likely path is continued enterprise expansion across provider revenue-cycle workflows.

Funding supports health-system deployments, model quality, integrations, and clinical/RCM expertise. Sellers should target measurable ROI, security, HIPAA readiness, interoperability, evaluation workflows, and implementation speed for hospital environments.